Goran Palčevski

Goran Palčevski

Auto-generated profile, based on publicly available information

Goran Palčevski

Clinical Hospital Center Rijeka

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 October 2021
Verified
Conference Paper
Open access
PDF file
LILana Ivković
Lana Ivković
IHIva Hojsak
Iva Hojsak
IMIvana Trivic Mazuranic
Ivana Trivic Mazuranic
SSSara Sila
Sara Sila
PHPero Hrabač
Pero Hrabač
SKSanja Kolacek
Sanja Kolacek
Primary aims of this study were to determine the annual incidence and geographic distribution of pediatric inflammatory bowel disease (IBD), respectively existence of north to south gradient in Croatia as well as baseline characteristics at the time of diagnosis. Secondary aim was to compare data on frequency and distribution of pediatric IBD in two consecutive years. This is a prospective, cohort, multicenter observational study based on the data obtained from the newly established Croatian national registry for children with inflammatory bowel disease. Children and adolescents younger than 18 years diagnosed with IBD, according to revised Porto criteria, in time period between June 1st, 2016 and May 31st, 2017 were recruited. In order to validate obtained data and to monitor trends in the incidence of the disease, the data were also gathered for the period from June 1st, 2017 to May 31st, 2018. In season 2016/2017, 51 new cases of pediatric IBD were identified; 19 (37.3%) Crohn’s disease (CD), 28 (54.9%) ulcerative colitis (UC) and 8 (7.8%) IBD unclassified (IBD-U). Male preponderance of all three types of the disease was noticed (CD 52.6%, UC 60.7%, IBD-U 75%). The median age at diagnosis was 14.8 years; 15.3 for CD, 13.9 for UC, and 14.5 years for IBD-U. Female patients were slightly older than males, but without statistically significant difference (p=0.279). With 723,552 children younger than 18 years in Croatia in 2017, the annual incidence of pediatric IBD per 100,000 persons per year was 7.05 (2.62 for CD, 3.87 of UC and 0.55 for IBD-U). The lowest incidence was found in Dubrovnik-Neretva and Split-Dalmatia County (4.50-4.85/100,000 children up to 18 years of age/year), and the highest was found in Meðimurje County (22.80/100,000 children up to 18 years of age/year). Existence of north to south gradient was observed with almost two times higher incidence in northern region compared with southern parts of the country (8.38/100,000 vs. 4.26/100,000). Data from consecutive season (2017/2018) identified 50 new cases of pediatric IBD, with higher proportion of CD (44%) compared to year before. The incidence of pediatric IBD in Croatia is 7.05 per 100,000 persons younger than 18 years per year, with significant decreasing trend in incidences between northern and southern regions of the country.

11 October 2021
Verified
Conference Paper
Open access
PDF file
KDKristina Baraba Dekanić
Kristina Baraba Dekanić
IAIvona Butorac Ahel
Ivona Butorac Ahel
LRLucija Ruzman
Lucija Ruzman
MMMarina Milinović
Marina Milinović
GPGoran Palčevski
Goran Palčevski
Celiac disease (CD) is an autoimmune disease triggered by gluten in genetically predisposed individuals with reported global prevalence in children from 0.31% to 0.9%. Despite the increasing prevalence of CD, many patients remain undiagnosed. Several point-of-care tests (POC) for CD have been developed that can be used as useful screening tool. We aimed to determine the prevalence of CD in first-grade pupils in Primorje-Gorski Kotar county, Croatia using POC test. Methods: Biocard celiac test that detects IgA antibodies to tissue transglutaminase in whole blood was used to screen for celiac disease in healthy first-grade children born in 2011 and 2012 who consumed gluten without restrictions. Results: 1478 children were tested and none of them were tested positive with rapid test. In 10 children (0,6%) IgA deficiency has been suspected; only 4 of them agreed to be tested further for total IgA, anti-tTG and anti DGP antibodies. IgA deficiency was confirmed in 3 patients and in all 4 children CD has been excluded. Conclusion: In this, to our knowledge first prospective study in Croatia, we haven’t found children with celiac disease. Further research is needed to establish the true epidemiology of CD in Primorje-Gorski Kotar County and to confirm the value of rapid test in comparison with standard antibody CD testing.

11 October 2021
Verified
Conference Paper
Open access
PDF file
IDIva Dumančić
Iva Dumančić
KDKristina Baraba Dekanić
Kristina Baraba Dekanić
IAIvona Butorac Ahel
Ivona Butorac Ahel
GPGoran Palčevski
Goran Palčevski
Aim The aim of the study was to determine the frequency of individual indications, total number of esophagogastroduodenoscopies (EGDS) and pathohistological (PH) findings at the Pediatric Clinic, Clinical Hospital Center ( CHC ) Rijeka. The frequency of therapeutic interventions for foreign body extraction, the most common types of ingested objects, the frequency of ingestion of acid and alkalis, and the placement of PEG were also considered. Materials and Methods The medical records of all patients undergoing EGDS from January 2007 to December 2017 were reviewed retrospectively. In the analysis of the obtained data, the reasons for performing EGDS in each patient were recorded. The sample for PH analysis was taken based on the assesment of the physician who performed the examination (pediatric gastroenterologist). Results The total number of examinations performed was 1022. The most common indications for EGDS were: dyspepsia 32% (n =327), abdominal pain 21% (n= 211), and celiac disease 16% (n = 166). The most common endoscopic findings were : gastritis 50% (n =450), normal findings 35% (n = 325) and esophagitis 9% (n= 84). The most common PH findings were: normal 43% (n = 390), gastritis 23% (n=210), and duodenitis 15% (n =133). Of the total number of examinations, endoscopy was therapeutic in 10% (n= 98) of cases. The most common therapeutic indications were: foreign body ingestion 5% (n =51), PEG placement 3% (n= 35), and acid and alkali ingestion 1% (n=12). Conclusion The results obtainted are consistent with those of other studies and may indicate areas for additional education of staff and a starting point for future research on the topic.

11 October 2021
Verified
Conference Paper
Open access
PDF file
LILana Ivković
Lana Ivković
IHIva Hojsak
Iva Hojsak
IMIvana Trivic Mazuranic
Ivana Trivic Mazuranic
SSSara Sila
Sara Sila
PHPero Hrabač
Pero Hrabač
SKSanja Kolacek
Sanja Kolacek
Aims of this study were to determine the phenotype of pediatric inflammatory bowel disease (IBD) in patients in Croatia at the time of disease presentation, evaluate diagnostic and therapeutic approaches and investigate early disease-course in one-year follow-up. During a one-year time period (June 1st, 2016 to May 31st, 2017), children and adolescents younger than 18 years of age in Croatia with newly diagnosed IBD were prospectively recruited into Croatian national registry. Data on disease location and behavior (according to Paris classification), diagnostic evaluation and therapy used for inducing and maintaining remission were collected. One-year follow-up data examined relapse rates, as well as modification of medical therapy. A total of 51 newly diagnosed patients were recruited: 19 (37.3%) Crohn’s disease (CD), 28 (54.9%) ulcerative colitis (UC) and 4 (7.8%) IBD – unclassified (IBD-U). Most common location in CD was ileocolonic (L3) disease in 52.6%, followed by distal 1/3 ileal disease (L1) in 31.6%. Patients with UC most commonly had pancolitis (E4) (53.6%), and 7.1% presented with ever severe form of the disease (S1). The recommended complete diagnostic algorithm was performed only in 29.4% of our patients. First line therapy used in CD was exclusive enteral nutrition (EEN) for remission induction (84.2%) and azathioprine for remission maintenance (73.7%). In patients with UC, aminosalicylates were the most common drug used (89.3%). By the end of the first year 41.2% of CD and 53.9% of UC patients had a relapse and required escalation of treatment. Median time to the first relapse was 5 (5-11) months. Following potential risk factors for relapse were examined: age (p = 0.769), gender (p = 0.091), Z – score body mass index for age (p = 0.914), Z – score height for age (p = 0.087), Pediatric Crohn’s Disease Activity Index (p = 0.947), Pediatric Ulcerative Colitis Activity Index (p = 0.245), EEN (p = 0.605), but none of them were statistically significant. Our data confirm extensive intestinal involvement in pediatric IBD and relatively high relapse rate during the first year of follow-up. More effort should be invested on the national level to implement more stringent adherence to the current European guidelines.

11 October 2021
Verified
Conference Paper
Open access
PDF file
IAIvona Butorac Ahel
Ivona Butorac Ahel
KDKristina Baraba Dekanić
Kristina Baraba Dekanić
GPGoran Palčevski
Goran Palčevski
JRJelena Roganovic
Jelena Roganovic
Gilbert syndrome (GS) and hereditary spherocytosis (HS) are hereditary diseases with high prevalence rates and similar symptoms. The calculated coexistence of these two diseases is 15-35/million births. Severe hyperbilirubinemia compared with the degree of hemolysis in patients with HS should raise suspicion of associated clinical conditions such as GS, glucose-6-phosphate-dehydrogenase deficiency or thalassemia. We present the case of a 21-month-old girl with HS and GS. The diagnosis of HS was established by osmotic fragility test results in the age of 40 days. During infancy the patient had several hemolytic episodes precipitated by upper respiratory tract infections, requiring transfusion therapy. Bilirubin levels were around 100 mmol/l. At the age of 21 months during viral infection, an unusually high unconjugated hyperbilirubinemia was noticed (total bilirubin/direct level 239/13 mmol/l) with mild anemia in the absence of severe hemolysis. As hyperbilirubinemia could not be explained by hemolysis, further evaluation was performed. Genotyping of the conjugation enzyme uridine diphosphate-glucuronosyltransferase confirmed GS. The girl has been followed-up regularly, with consistently higher values of total bilirubin. A trial with phenobarbitone resulted in a rapid fall in bilirubin levels (below 34 mmol/l) followed. Our case confirms that the possibility of the coexistence of GS and HS should be considered in patients with inappropriately high serum bilirubin levels when compared with the severity of HS.